Press Releases

Press Releases

Marcy l’Etoile (France) and Lexington, MA (U.S.) – November 15, 2012 — bioMérieux and Quanterix announced today that they have entered into a strategic agreement that gives bioMérieux worldwide exclusive rights to Quanterix’s Simoa technology in clinical laboratories and for industrial applications…
Lexington, Mass. – January 23, 2014 – Quanterix Corporation, Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that they have been selected as a winner of the GE and NFL Head Health…
Lexington, Mass--(BUSINESS WIRE)– December 16, 2014 Quanterix, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the opening of The Simoa Accelerator, a dedicated laboratory environment for custom assay…
LEXINGTON, MA – May 20, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that a study, prominently featuring Simoa’s multiplexing capabilities, has been published in The…
LEXINGTON, MA – August 26, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that The Journal of Clinical Chemistry has published a new study in which its single molecule array technology (Simoa) was used to measure cardiac troponin I (cTnI) levels with both high…
January 27, 2016
Quanterix announces its expansion into several prominent APAC markets.    
May 24, 2016
Quanterix announces that the Company’s CEO and Executive Chairman, Kevin Hrusovsky, will be presenting at the 5th Annual One Mind Summit.
January 5, 2017
Presenting for the second consecutive year, Quanterix will be kicking off the 2017 conference by highlighting the Company’s position to transform precision health
May 17, 2017
New panel offers unmatched sensitivity to simultaneously measure four proven neurological protein biomarkers in blood and cerebrospinal fluid within a single test
CAMBRIDGE, MA – November 2, 2010 – Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP…